Recent 8-K filings for GOVX
Highest-materiality recent filing
GeoVax reports Q2 net loss of $5.1M; awarded up to $388M BARDA contract for COVID vaccine trial
- Net loss $5.1M ($1.99/share) vs $5.9M ($3.79) in Q2 2023; R&D expenses $4.3M.
- BARDA Project NextGen award for GEO-CM04S1 Phase 2b trial; total value $367-388M incl. Allucent.
-
GeoVax prices $3M private placement offering at $1.4799 per unit with warrants
Gross proceeds ~$3M; net proceeds ~$2.7M after placement agent fees and expenses.
-
GeoVax Q1 2026 net loss $5.3M; cash $1.3M; advances GEO-MVA Phase 3
Net loss of $5.3M for Q1 2026 vs $5.4M in Q1 2025; no revenue vs $1.6M prior (BARDA contract terminated).
-
GeoVax reports 2025 net loss $21.5M; Phase 3 trial for mpox vaccine planned H2 2026
Net loss $21.5M ($22.40/share) vs $25.0M ($120.46/share) in 2024; revenue $2.5M from BARDA contract.
-
GeoVax raises ~$1M gross in registered direct offering priced at $2.31/share
Offering of 432,902 shares (or pre-funded warrants) at $2.31/share; net proceeds ~$865,000.
-
GeoVax Labs effects 1-for-25 reverse stock split effective January 9, 2026
Each 25 shares of common stock automatically combined into 1 share; no fractional shares issued.
-
GeoVax raises ~$3.2M in public offering of 13.2M units at $0.245/unit
Offering of 13,244,896 common units at $0.245/unit, each consisting of one share plus warrants for two shares.
-
GeoVax Q3 net loss $6.3M ($0.31/sh); BARDA contract terminated; Mpox vaccine accelerated
Net loss of $6.3M vs $5.8M in Q3 2024; per-share loss improved to $0.31 from $0.91 due to share count change.
-
GeoVax raises ~$2.5M in registered direct offering; issues shares and warrants at $0.63
3,968,256 shares sold at $0.63 each with warrants to buy 11,904,768 shares at $0.63.
-
GeoVax receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified GeoVax on July 31, 2025, that closing bid price was below $1.00 for 30 consecutive business days.
-
GeoVax raises ~$6M in public offering of 9.2M units at $0.65/unit
Offering of 9,235,000 units at $0.65/unit, each unit = 1 share + warrant to buy 2 shares.
-
GeoVax Q1 net loss narrows to $5.4M; BARDA award ended, COVID vaccine data due Q2 2025
Net loss $5.4M (vs $5.9M Q1 2024); revenue $1.6M from BARDA contract (none prior year).
-
BARDA terminates GeoVax's Phase 2b COVID-19 vaccine contract for convenience
On April 11, 2025, GeoVax received stop-work notice from ATI/BARDA for Project Agreement RRPV-24-04-NGVx-006.
-
GeoVax FY2024 net loss $25.0M; BARDA award yields $4.0M revenue; key trials advancing
Net loss $25.0M vs $26.0M in 2023; revenue of $4.0M from BARDA Project NextGen contract (no revenue in 2023).
-
GeoVax Labs raises $4.5M in registered direct offering, amends existing warrants
Issued 3,435,115 shares or equivalents and common warrants at $1.31/unit, gross proceeds ~$4.5M.
-
GeoVax Labs regains Nasdaq compliance with $8.5M stockholders' equity
Received Nasdaq notice on Nov 18, 2024 confirming compliance with Listing Rule 5550(b)(1) based on $8,503,876 stockholders' equity as of Sep 30, 2024.
-
GeoVax Q3 net loss $5.8M ($0.91/share); BARDA NextGen trial on track; special meeting adjourned
Net loss $5.8M for Q3 2024 ($0.91/share) vs $8.4M ($4.75/share) in Q3 2023; nine-month net loss $16.7M ($4.52/share).
-
GeoVax Labs boosts ATM equity offering capacity from $4.5M to $30M
Maximum aggregate offering price under Sales Agreement with A.G.P./Alliance Global Partners increased from $4,486,846 to $30,000,000.
-
GeoVax raises ~$5.0M in registered direct offering at $5.125/share with warrants
Offering of 837,500 common shares at $5.125/share and 138,110 pre-funded warrants at $5.12499, exercise price $0.0001.
-
GeoVax raises ~$8.5M in registered direct offering of 1.7M shares at $5.00 each
Gross proceeds $8.5M; net proceeds ~$7.855M after fees and expenses.
-
GeoVax reports Q2 net loss of $5.1M; awarded up to $388M BARDA contract for COVID vaccine trial
Net loss $5.1M ($1.99/share) vs $5.9M ($3.79) in Q2 2023; R&D expenses $4.3M.
-
GeoVax raises ~$3.1M gross in offering of stock, pre-funded and common warrants
Offering of 1,085,000 shares (or equivalents) at $2.86; pre-funded warrants for 626,368 shares and common warrants for 2,170,000 shares.
-
GeoVax receives BARDA award up to $45M for Phase 2b COVID-19 vaccine trial
Direct award to GeoVax of ~$24.3M, potentially increasing to $45M, for manufacturing and clinical trial support.
-
GeoVax Labs receives Nasdaq delisting notice for failing $2.5M equity minimum
Notice received May 23, 2024; stockholders' equity as of March 31, 2024 below $2.5M requirement.
-
GeoVax Q1 net loss widens to $5.6M; cash drops to $0.8M, raising going-concern risk
Net loss of $5.6M ($2.47 per share) vs $4.0M ($2.30 per share) in Q1 2023.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material